Ignite Creation Date:
2025-12-24 @ 1:02 PM
Ignite Modification Date:
2026-02-11 @ 6:12 AM
Study NCT ID:
NCT03099161
Status:
TERMINATED
Last Update Posted:
2019-06-05
First Post:
2017-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Neoplasm | View |